drugset / Trial / NCT03446547
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC. Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months
Timeline
- Start
- 2017-12-04
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |